Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Commentary|Videos|April 9, 2025
Conversations About Food: The Role of the Psychiatrist in Patient Nutrition Status
Author(s)Ali Beckman, MS, RD, LD, CEDS-C
Listen
0:00 / 0:00
Here are the conversations you should be having with patients about food and diet.
Advertisement
Ali Beckman, MS, RD, LD, CEDS-C, discusses the types of conversations psychiatrists and mental health clinicians should be having with patients about food and diet. These conversations boil down to 4 important general topics.
- Are patients getting enough food?
- Are patients eating consistently, not just in 1 sitting or in giant caloric bursts? Blood sugar stabilization is critical.
- Are patients eating good quality food?
- Are patients eating a variety of food?
Ms Beckman is a registered dietitian, eating disorder specialist, certified intuitive eating counselor, and the director of Clinical Nutrition and Movement Services at Alsana.
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Are Clinicians Prepared to Counsel Patients About Psychedelics?
5